结直肠癌腹膜转移的治疗及合并症处理

doi:10.3969/j.issn.1671-7171.2019.05.034

Abstract
Figure/Table
References
Related Citation (15)

[1] 杜灵彬,李辉章,王悠清, 等.2013年中国结直肠癌发病与死亡分析[J].中华肿瘤杂志,2017,39(9):701-706.
[2] Siegel R,Ma J,Zou Z,et al. Cancer statistics, 2014[J] .CA Cancer J Clin,2014, 64(1):9-29.
[3] Koppe MJ,Boerman OC,Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies[J] .Ann Surg,2006, 243(2):212-222.
[4] Korkolis DP, Aggeli C, Passas I, et al. Peritoneal Carcinomatosis from colorectal cancer[J].Hellenic J Surg,2011,83(6):317-325.
[5] Ung L,Chua TC,David LM.Peritoneal metastases of lower gastrointestinal tract origin:a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy[J].J Cancer Res Clin Oncol,2013, 139: 1899-1908.
[6] Guend H,Patel S,Nash GM.Abdominal metastases from colorectal cancer: intraperitoneal therapy[J].J Gastrointest Oncol,2015,6(6):693-698.
[7] 中国医师协会结直肠肿瘤专委会腹膜肿瘤专业委员会. 结直肠癌腹膜转移诊治中国专家意见(2017)[J].中华结直肠疾病电子杂志, 2017,6(5):360-366.
[8] Sugarbaker PH.Carcinomatosis from gastrointestinal cancer[J].Ann Med,2004, 36(1): 9-22.
[9] Baratti D,Kusamura S,Deraco M.The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus[J].J Surg Oncol,2008, 98(4): 258-262.
[10] Marin D,Catalano C,Baski M,et al. 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings[J].Abdom Imaging,2010, 35(6): 694-700.
[11] 王枭杰,池畔,林惠铭, 等.建立影像学无远处转移结肠癌患者发生腹膜转移的列线图预测模型[J].中华胃肠外科杂志,2017,20(12):1387-1392.
[12] Hompes D,Tiek J,Wolthuis A, et al. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome[J] .Ann Oncol,2012, 23(12):3123-3129.
[13] Pande R,Sunga A,Levea C,et al. Significance of signet-ring cells in patients with colorectal cancer[J] .Dis Colon Rectum,2008, 51(1): 50-55.
[14] Kang H,O'Connell JB,Maggard MA,et al. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum[J] .Dis Colon Rectum,2005, 48(6): 1161-1168.
[15] Verhulst J,Ferdinande L,Demetter P, et al. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis[J] .J Clin Pathol,2012, 65(5): 381-388.
[16] Segelman J,Granath F,Holm T et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer[J] .Br J Surg,2012, 99(5):699-705.
[17] Nagata H,Ishihara S,Hata K,et al. Survival and Prognostic Factors for Metachronous Peritoneal Metastasis in Patients with Colon Cancer[J] .Ann Surg. Oncol,2017, 24(5):1269-1280.
[18] Falcone A,Ricci S,Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest[J].J Clin Oncol,2007, 25(13):1670-166.
[19] 宋岩, 李伟伟, 黄镜, 等. FOLFOXIRI方案治疗中国晚期结直肠癌患者的疗效和安全性[J].中华肿瘤杂志, 2017,39(5):380-383.
[20] 孙志伟, 王晰程, 贾军, 等. 不同原发部位转移性结直肠癌的化疗疗效差异分析[J].中华胃肠外科杂志,2016,10:1119-1123.
[21] Holch JW,Ricard I,Stintzing S,et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials[J] .Eur J Cancer,2017, 70: 87-98.
[22] Seymour MT,Trigonis I,Finan PJ,et al. A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer[J] .Eur J Surg Oncol,2008, 34(4):403-409.
[23] Sugarbaker PH,Van der Speeten K,Anthony Stuart O, et al. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis[J].Eur J Surg Oncol,2011,37(8):719-726.
[24] Verwaal VJ,van Ruth S,de Bree E,et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer[J].J Clin Oncol,2003, 21(20):3737-3743.
[25] 钟漓, 赵志, 朱小宝, 等. 腹腔内注射贝伐珠单抗治疗结直肠癌患者恶性腹腔积液的疗效和安全性评价[J].中华结直肠疾病电子杂志,2016,5(5):424-427.
[26] 王爱秋. 香菇多糖联合顺铂腹腔灌注治疗肿瘤患者腹腔积液的临床疗效[J].中国医药指南,2013,(6):596.
[27] 李露露, 张婵, 焦士洁, 等. 扶正固本颗粒治疗晚期结直肠癌合并贫血的临床研究[J].癌症进展,2017,15(9):1048-1051.
[28] 丁新, 肖秀英, 杨晓燕, 等. 复方苦参注射液联合FOLFOX4方案治疗晚期结直肠癌的临床观察[J].中国癌症杂志,2010,20(11):860-863.
[29] 唐晓玲, 熊墨年, 陈黎莉, 等. 益气清毒法综合治疗老年晚期结直肠癌的临床疗效[J].中国老年学杂志,2014,34(24):6908-6910.
[30] Gianotti Luca,Tamini Nicolò,Nespoli Luca, et al. A prospective evaluation of short-term and long-term results from colonic stenting for palliation or as a bridge to elective operation versus immediate surgery for large-bowel obstruction[J].Surg Endosc,2013, 27(3):832-842.